Johnson & Johnson (J&J) has shared positive long-term results from a phase 3 trial of its dual-acting IL-23 inhibitor Tremfya ...

Johnson & Johnson announces new data from Tremfya phase 3 QUASAR LTE study in adults with moderately-to-severely active ulcerative colitis: San Diego, California Tuesday, May 6, 2 ...

The "Hidradenitis Suppurativa Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's ...

Drug major Johnson & Johnson (JNJ) announced Monday positive new data from the Phase 3 ASTRO study evaluating TREMFYA (guselkumab) subcutaneous (SC) induction therapy ...

AbbVie snagged yet another spot among April’s highest TV ad spenders, as its Vraylar jumped two spots to eighth place with a ...

New long-term extension data from the Phase IIb/III QUASAR trial demonstrate that Tremfya (guselkumab) maintains durable ...

Johnson & Johnson (NYSE: JNJ) today announced new data from the TREMFYA® (guselkumab) Phase 3 QUASAR long-term extension (LTE) study in adults with moderately-to-severely active ulcerative colitis (UC ...

Recent years have seen significant advancements in UC treatment, offering renewed hope for patients seeking effective and ...

Many rheumatologic conditions such as rheumatoid arthritis and lupus often strike women during their reproductive years, with drugs being the primary therapies. Experts assembled by EULAR determined ...

The EC has granted marketing authorisation for Johnson & Johnson's (J&J) Tremfya to treat adults with ulcerative colitis (UC) ...

In 2024, the U.S. healthcare industry spent $6.1 billion on Pfizer’s COVID-19 therapy Paxlovid, a 6,922.8% increase from 2023 expenditure data, according to a recent study. The research, published ...

Johnson & Johnson (J&J) has announced that its dual-acting IL-23 inhibitor Tremfya (guselkumab) has been approved by the ...